Abstract
The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP in Inflammatory Bowel Disease: State of the Art
Volume: 12 Issue: 4
Author(s): Catalina Abad, Rosa Gomariz, James Waschek, Javier Leceta, Carmen Martinez, Yasmina Juarranz and Alicia Arranz
Affiliation:
Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.
Abstract: The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
Export Options
About this article
Cite this article as:
Abad Catalina, Gomariz Rosa, Waschek James, Leceta Javier, Martinez Carmen, Juarranz Yasmina and Arranz Alicia, VIP in Inflammatory Bowel Disease: State of the Art, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832576
DOI https://dx.doi.org/10.2174/187153012803832576 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Effect of Gender on Main Clinical Chemistry Parameters in Aged Rats
Current Aging Science Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Inhibition of Platelet Adhesion to Collagen as a New Target for Antithrombotic Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry On the Interaction Between Human IQGAP1 and Actin
Protein & Peptide Letters In Vitro Antioxidant Activity of Selected Medicinal Plants Reported in Ancient Ayurveda Traditions
Current Traditional Medicine Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Periodontal Disease and Periodontal Tissue Regeneration
Current Stem Cell Research & Therapy Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Ca2+-Dependent Signaling Pathways in the Heart: Potential Drug Targets for Cardiac Disease
Current Drug Targets - Cardiovascular & Hematological Disorders